drugset / Trial / NCT01205685
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers. OSI-906 attacks a different part of the cancer cell that helps them live and grow. Studies done in the laboratory show that OSI-906 can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers.
Timeline
- Start
- 2010-05
- Primary completion
- 2011-07
- Completion
- 2011-07
Outcome
Outcome not reported
Stopped: “PI closed study early, all patients experienced severe toxicities and progressed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 50 mg | Oral |
| Subject | Erlotinib | Small molecule | 75 mg | Oral |
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | linsitinib | Small molecule | 100 mg | Oral |
| Subject | linsitinib | Small molecule | 150 mg | Oral |
| Background | Goserelin | Other / unclassified | 3.6 mg | Other |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |